DAVOS, Switzerland, Jan 24 (Reuters) - U.S. drugmaker Eli Lilly and Co (LLY.N: Quote, Profile, Research) remains “very committed” to developing an inhaled form of insulin, despite recent decisions by competitors to abandon rival products.
DAVOS, Switzerland, Jan 24 (Reuters) - U.S. drugmaker Eli Lilly and Co (LLY.N: Quote, Profile, Research) remains “very committed” to developing an inhaled form of insulin, despite recent decisions by competitors to abandon rival products.
